NanoViricides(NNVC)

搜索文档
NanoViricides touts antiviral NV-387 as tool against new COVID variant
Proactiveinvestors NA· 2025-06-18 20:36
公司概况 - 公司是全球领先的实时多媒体新闻提供商 业务涵盖新闻发布 活动组织 投资者关系管理及投资研究 [1] - 新闻团队独立运作 由经验丰富的专业记者组成 内容覆盖全球投资市场 [1] - 公司在伦敦 纽约 多伦多 温哥华 悉尼和珀斯等全球主要金融中心设有分支机构 [2] 内容覆盖领域 - 专注于中小市值公司 同时覆盖蓝筹股 大宗商品及广泛投资领域 [2] - 重点报道生物技术 制药 采矿与自然资源 电池金属 石油天然气 加密货币及新兴数字技术 电动汽车技术等行业 [3] 技术应用 - 积极采用前沿技术辅助内容生产 团队拥有数十年专业经验 [4] - 选择性使用自动化工具及生成式AI 但所有内容均经过人工编辑和审核 [5]
NanoViricides commissions animal study of broad-spectrum antiviral for measles
Proactiveinvestors NA· 2025-06-04 21:03
About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...
NanoViricides president backs FDA's targeted COVID booster policy shift
Proactiveinvestors NA· 2025-05-22 21:24
About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...
NanoViricides advances NV-387 antiviral program, eyes Phase II trials for Mpox
Proactiveinvestors NA· 2025-05-16 21:10
About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...
NanoViricides(NNVC) - 2025 Q3 - Quarterly Report
2025-05-16 04:31
QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2025 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Address of principal executive offices and zip code) (203) 937-6137 (Company's telephone number, including area code) Indicate by check mark whether the Company (1) has filed ...
NanoViricides progresses antiviral portfolio as measles and MPox threats rise
Proactiveinvestors NA· 2025-05-14 21:09
About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...
NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC
Proactiveinvestors NA· 2025-05-08 20:58
About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...
NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC
Newsfile· 2025-05-05 18:30
公司动态 - NanoViricides Inc 将参加 D Boral Capital 首届全球会议 会议于2025年5月14日在纽约广场酒店举行 [2] - 公司总裁兼执行主席 Anil R Diwan 将在会议当天上午9点至下午3点主持一对一会议 [3] - 有意与公司管理层会面的投资者需联系 D Boral Capital 的 John Perez 进行注册 [3] 公司业务与技术 - 公司开发了新型广谱抗病毒药物 NV-387 该药物可治疗多种不相关的病毒感染 其革命性堪比青霉素对细菌感染的治疗 [4] - NV-387已完成一期人体临床试验 正在准备申请二期临床试验 用于治疗非洲地区的MPox [4] - 公司计划开展针对RSV 流感 COVID和其他呼吸道感染的临床试验 NV-387预计对麻疹病毒感染也有效 [4] - 公司还开发了治疗几乎所有疱疹病毒感染的NV-HHV-1 以及治疗HIV/AIDS的NV-HIV-1 [4] - 公司技术独特 可开发病毒无法逃脱的药物 克服了传统抗体疫苗和小分子疗法面临的病毒变异问题 [4] - 仅上述三种产品的市场规模就达到200亿至300亿美元 [4] 会议主办方 - D Boral Capital 是一家总部位于纽约的投资银行 为中等规模和新兴成长型公司提供咨询和融资解决方案 [5] - 公司在全球范围内为客户提供战略指导 资本来源覆盖美国 亚洲 欧洲 中东和拉丁美洲 [5] - D Boral Capital 是华尔街的领导者 通过各类产品完成了约350笔交易 累计筹集资金超过250亿美元 [6]
NanoViricides advances measles drug development amid rising US cases
Proactiveinvestors NA· 2025-04-29 21:23
文章核心观点 Proactive为全球投资受众提供商业和金融新闻内容 专注中小盘市场 也关注蓝筹公司等 采用技术辅助内容创作 所有内容由人类编辑和撰写 [2][3][5] 关于编辑 - 编辑Angela Harmantas有超15年北美股票市场报道经验 专注初级资源股 曾为多国领先行业出版物报道 还从事过投资者关系工作 [1] 关于出版商 - Proactive金融新闻和在线广播团队为全球投资受众提供快速 易获取 有信息价值和可操作的商业和金融新闻内容 内容由经验丰富且合格的新闻记者团队独立制作 [2] - Proactive新闻团队遍布世界主要金融和投资中心 在多地设有办事处和工作室 [2] 市场与内容覆盖 - 公司是中小盘市场专家 也让社区了解蓝筹公司 大宗商品和更广泛的投资故事 内容吸引积极的个人投资者 [3] - 团队提供涵盖多个领域的新闻和独特见解 包括生物技术和制药 矿业和自然资源等 [3] 技术应用 - Proactive积极采用技术 人类内容创作者经验丰富 团队使用技术辅助和优化工作流程 [4] - Proactive有时会使用自动化和软件工具 包括生成式AI 但所有发布内容均由人类编辑和撰写 [5]
NanoViricides evaluating antiviral drug NV-387 for measles treatment
Proactiveinvestors NA· 2025-04-14 20:59
文章核心观点 Proactive为全球投资受众提供商业和金融新闻内容 专注中小盘市场 也关注蓝筹公司等 采用技术辅助内容创作 所有内容由人类编辑和撰写 [2][3][5] 关于编辑 - Angela Harmantas是Proactive的编辑 有超15年北美股票市场报道经验 专注初级资源股 曾为多国领先行业出版物报道 还从事过投资者关系工作 [1] 关于出版商 - Proactive金融新闻和在线广播团队为全球投资受众提供快速 易获取 有信息价值和可操作的商业和金融新闻内容 内容由经验丰富且合格的新闻团队独立制作 [2] - Proactive新闻团队遍布世界主要金融和投资中心 在多地设有办事处和工作室 [2] 市场与内容覆盖 - 公司是中小盘市场专家 也让社区了解蓝筹公司 大宗商品和更广泛的投资故事 内容吸引积极的个人投资者 [3] - 团队提供涵盖多个领域的新闻和独特见解 包括生物技术和制药 矿业和自然资源等 [3] 技术应用 - Proactive积极采用技术 人类内容创作者经验丰富 团队使用技术辅助和优化工作流程 [4] - Proactive有时会使用自动化和软件工具 包括生成式AI 但所有发布内容均由人类编辑和撰写 符合内容制作和搜索引擎优化最佳实践 [5]